Fadanafil

Fadanafil (XZP-5849) is a selective **phosphodiesterase type 5 (PDE5) inhibitor**. It works by blocking the phosphodiesterase type 5 enzyme, which breaks down cyclic guanosine monophosphate (cGMP). By inhibiting this enzyme, fadanafil is expected to increase cGMP levels, leading to smooth muscle relaxation and increased blood flow in specific areas of the body. As of the information available, it was in **early clinical development**. A **Phase 1 trial** was conducted in Chinese healthy adult male subjects to evaluate its safety, tolerability, and pharmacokinetics. This trial was a double-blind, placebo-controlled, single ascending dose study involving approximately 66 subjects across 8 cohorts. Based on the class of drugs it belongs to, PDE5 inhibitors are commonly used for conditions such as erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.

Other names

frodanafil复达那非